US Drug Recall Register
Class III · Low risk Terminated Initiated Aug 2, 2017 (9 years ago)

Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose…

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Moisture Limits: out of specification test results for water content obtained during stability testing.

What was recalled

Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx only, Mfd for: Watson Laboratories, Inc., Corona, CA 92880, Mfd by: Patheon Pharmaceuticals, Inc., Cincinnati, OH 43215, NDC 0591-0844-15

Recalling firm
Teva Pharmaceuticals USA
NDC code
0591-0844-15
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1058-2017

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Glipizide recalls

See all